Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study)

Mercedes Rivas-Lasarte, Jesús Álvarez-García, Juan Fernández-Martínez, Alba Maestro, Laura López-López, Eduard Solé-González, Maria J Pirla, Nuria Mesado, Sonia Mirabet, Paula Fluvià, Vicens Brossa, Alessandro Sionis, Eulàlia Roig, Juan Cinca, Mercedes Rivas-Lasarte, Jesús Álvarez-García, Juan Fernández-Martínez, Alba Maestro, Laura López-López, Eduard Solé-González, Maria J Pirla, Nuria Mesado, Sonia Mirabet, Paula Fluvià, Vicens Brossa, Alessandro Sionis, Eulàlia Roig, Juan Cinca

Abstract

Aims: Lung ultrasound (LUS) is a useful tool with which to assess subclinical pulmonary congestion and to stratify the prognosis of patients with heart failure (HF). The aim of this study was to evaluate whether an LUS-guided follow-up protocol improves the outcomes of patients with HF.

Methods and results: In this single-blind clinical trial, 123 patients admitted for HF were randomized to either a standard follow-up (n = 62, control group) or a LUS-guided follow-up (n = 61, LUS group). The primary endpoint was a composite of urgent visit, hospitalization for worsening HF and death during follow-up. Visits were scheduled at 14, 30, 90 and 180 days after discharge. Treating physicians were encouraged to modify diuretic therapy in accordance with the number of B-lines recorded by LUS. The mean ± standard deviation (SD) age of the patients was 69 ± 12 years and 72% were male. The mean ± SD left ventricular ejection fraction was 39 ± 14%. The hazard ratio for the primary outcome in the LUS group was 0.518 [95% confidence interval (CI) 0.268-0.998; P = 0.049], mainly resulting from a decrease in the number of urgent visits for worsening HF. The number of patients needed to treat to avoid an event was 5 (95% CI 3-62). Other secondary endpoints such as N-terminal pro-B-type natriuretic peptide reduction were not achieved. The safety parameters were similar in the two groups. Patients in the LUS group received more loop diuretics [51 (91%) vs. 42 (75%); P = 0.02] and showed an improvement in the distance achieved in the 6-min walking test [60 m (interquartile range: 29-125 m) vs. 37 m (interquartile range: 5-70 m); P = 0.023].

Conclusions: Tailored LUS-guided diuretic treatment of pulmonary congestion in this proof-of-concept study reduced the number of decompensations and improved walking capacity in patients with HF. LUS is a non-invasive, safe and easy-to-use technique with potential clinical applicability to guide pulmonary congestion treatment in patients with HF.

Keywords: Biomarker; Clinical trial; Heart failure; Lung ultrasound; Pulmonary congestion.

© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

References

    1. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-2736.
    1. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-888.
    1. Chaudhry A, Singer AJ, Chohan J, Russo V, Lee C. Interrater reliability of hemodynamic profiling of patients with heart failure in the ED. Am J Emerg Med 2008;26:196-201.
    1. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J 2016;37:2097-2104.
    1. Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, Hempel D, Wilson C, Frasure SE, Jhund PS, Cheng S, Solomon SD. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J 2016;37:1244-1251.
    1. Öhman J, Harjola VP, Karjalainen P, Lassus J. Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. ESC Heart Fail 2018;5:120-128.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
    1. Volpicelli G, Lichtenstein DA, Kirkpatrick AW, Noble VE, Tsung JW, Reissig A, Rouby J, Arbelot C, Silva F. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med 2012;38:577-591.
    1. Ferrero-Gregori A, Álvarez-García J, Solé González E, Mirabet Pérez S, Cinca J, Roig E. Prospective validation of the Redin-SCORE to predict the risk of rehospitalization for heart failure in a contemporary cohort of outpatients. Rev Esp Cardiol 2016;69:1224-1225.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2012;10:28-55.
    1. Platz E, Jhund PS, Girerd N, Pivetta E, McMurray JJV, Peacock WF, Masip J, Martin-Sanchez FJ, Miró Ò, Price S, Cullen L, Maisel AS, Vrints C, Cowie MR, DiSomma S, Bueno H, Mebazaa A, Gualandro DM, Tavares M, Metra M, Coats AJS, Ruschitzka F, Seferovic PM, Mueller C. Expert consensus document: reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. Eur J Heart Fail 2019;21:844-851.
    1. Formiga F, Chivite D, Manito N, Casas S, Llopis F, Pujol R. Hospitalization due to acute heart failure. Role of the precipitating factors. Int J Cardiol 2007;120:237-241.
    1. Damy T, Kallvikbacka-Bennett A, Zhang J, Goode K, Buga L, Hobkirk J, Yassin A, Dubois-Rand JL, Hittinger L, Cleland JGF, Clark AL. Does the physical examination still have a role in patients with suspected heart failure? Eur J Heart Fail 2011;13:1340-1348.
    1. Anand IS, Veall N, Kalra GS, Ferrari R, Sutton G, Lipkin D, Harris P, Poole-Wilson PA. Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones. Eur Heart J 1989;10:445-450.
    1. Gadsbøll N, Høilund-Carlsen PF, Nielsen GG, Berning J, Brunn NE, Stage P, Hein E, Marving J, Løngborg-Jensen H, Jensen BH. Symptoms and signs of heart failure in patients with myocardial infarction: reproducibility and relationship to chest X-ray, radionuclide ventriculography and right heart catheterization. Eur Heart J 1989;10:1017-1028.
    1. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
    1. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure. Results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 2009;55:53-60.
    1. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Mark DB, Piña IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O'Connor CM. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2017;318:713-720.
    1. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, Bayés-Genis A, Tijssen JGP, Pinto YM, Kok WE. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: the PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation 2018;137:1671-1683.
    1. Bajaj NS, Patel N, Prabhu SD, Arora G, Wang TJ, Arora P. Effect of NT-proBNP-guided therapy on all-cause mortality in chronic heart failure with reduced ejection fraction. J Am Coll Cardiol 2018;71:951-952.
    1. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LWM, Erntell H, Persson H, O'Connor CM, Moertl D, Karlström P, Dahlström U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014;35:1559-1567.
    1. Núñez J, Llàcer P, Bertomeu-González V, Bosch MJ, Merlos P, García-Blas S, Montagud V, Bodí V, Bertomeu-Martínez V, Pedrosa V, Mendizábal A, Cordero A, Gallego J, Palau P, Miñana G, Santas E, Morell S, Llàcer A, Chorro FJ, Sanchis J, Fácila L; CHANCE-HF Investigators. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail 2016;4:833-843.
    1. Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017;70:1875-1886.
    1. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-666.
    1. Dhruva SS, Krumholz HM. Championing effectiveness before cost-effectiveness. JACC Heart Fail 2016;4:376-379.
    1. Picano E, Scali MC, Ciampi Q, Lichtenstein D. Lung ultrasound for the cardiologist. JACC Cardiovasc Imaging 2018;11:1692-1705.
    1. Chiem AT, Chan CH, Ander DS, Kobylivker AN, Manson WC. Comparison of expert and novice sonographers' performance in focused lung ultrasonography in dyspnea (FLUID) to diagnose patients with acute heart failure syndrome. Acad Emerg Med 2015;22:564-573.
    1. Gargani L, Frassi F, Soldati G, Tesorio P, Gheorghiade M, Picano E. Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: a comparison with natriuretic peptides. Eur J Heart Fail 2008;10:70-77.
    1. Platz E, Lattanzi A, Agbo C, Takeuchi M, Resnic FS, Solomon SD, Desai AS. Utility of lung ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail 2012;14:1276-1284.
    1. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, de Filippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015;17:544-548.
    1. Pivetta E, Goffi A, Nazerian P, Castagno D, Tozzetti C, Tizzani P, Tizzani M, Porrino G, Ferreri E, Busso V, Morello F, Paglieri C, Masoero M, Cassine E, Bovaro F, Grifoni S, Maule MM, Lupia E. Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department: a randomized controlled trial. Eur J Heart Fail 2019;21:754-766.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe